ANI Pharma posts Q3 2026 revenue growth and acquires Egetis Therapeutics
ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, an increase of 27.6% year-over-year, alongside its strategic offer to acquire Egetis Therapeutics for market growth in rare diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed